论文部分内容阅读
目的:探讨不同剂量孕三烯酮对中重度子宫内膜异位症术后的临床疗效和不良作用。方法:选择中重度卵巢子宫内膜异位症术后患者124例,术后30例不用药物治疗(对照组),术后52例服用孕三烯酮(A组),每次2.5 mg,每周2次,术后42例服用孕三烯酮(B组),每次2.5 mg,每周3次,观察3组的疗效、ALT、体重增长和不良反应。结果:A组和B组的3个月有效率分别为53.85%和71.43%,均高于对照组(P<0.05);A组和B组6个月的有效率分别为59.62%和69.05%,均高于对照组(P<0.05);A组和B组6个月的复发率分别为15.38%和9.52%,均低于对照组(P<0.05);A组和B组ALT 6个月为(43.36±1.42)U/L和(46.20±2.88)U/L,高于对照组(P<0.05);B组3个月体重增加为(1.29±0.07)kg,高于对照组(0.12±0.04)kg(P<0.05);A组和B组6个月体重增加(1.34±0.17)kg和(2.56±0.38)kg,均高于对照组(0.53±0.11)kg,且B组高于A组(P<0.05)。B组3个月痛经发生率为9.52%,低于对照组的20.00%,A组和B组6个月痛经发生率为9.62%和7.14%,均低于对照组(P<0.05)。B组3个月痤疮发生率为11.90%,高于对照组(P<0.05);A组和B组6个月痤疮发生率为11.54%和26.19%,均高于对照组,且B组高于A组(P<0.05)。结论:术后应用孕三烯酮治疗中重度子宫内膜异位症术后可以提高治疗效率、降低复发率,但不要忽视高剂量的不良作用。
Objective: To investigate the clinical efficacy and adverse effects of different doses of gestrinone on postoperative patients with moderate-severe endometriosis. Methods: A total of 124 patients with moderate or severe ovarian endometriosis were selected. Thirty patients were treated with no medication after operation (control group). Fifty-two patients received gestrinone (2.5 mg each time) 2 times a week, after taking 42 patients with gestrinone (B group), each 2.5 mg three times a week to observe the efficacy of the three groups, ALT, weight gain and adverse reactions. Results: The 3-month effective rates of group A and group B were 53.85% and 71.43%, respectively, which were higher than that of control group (P <0.05). The effective rates of group A and group B at 6 months were 59.62% and 69.05% (P <0.05). The recurrence rates at 6 months in group A and group B were 15.38% and 9.52%, respectively, which were lower than those in control group (P <0.05). ALT in group A and group B were 6 (43.36 ± 1.42) U / L and (46.20 ± 2.88) U / L, respectively, which were significantly higher than those of the control group (P <0.05). The weight gain of group B at 3 months was (1.29 ± 0.07) 0.12 ± 0.04) kg (P <0.05). The body weight of group A and group B were (1.34 ± 0.17) kg and (2.56 ± 0.38) kg at 6 months, Higher than A group (P <0.05). The incidence of dysmenorrhea in group B at 3 months was 9.52%, which was lower than 20.00% in control group. The incidences of dysmenorrhea in group A and group B at 6 months were 9.62% and 7.14%, both lower than those in control group (P <0.05). The incidence of acne in group B at 3 months was 11.90%, higher than that in control group (P <0.05). The acne incidence rates in group A and group B at 6 months were 11.54% and 26.19%, respectively, which were higher than those in control group In group A (P <0.05). Conclusion: Gestrinone treatment of moderate and severe endometriosis postoperative can improve the treatment efficiency and reduce the recurrence rate, but do not ignore the adverse effects of high doses.